ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

DYN Dyne Therapeutics Inc

33.30
-0.39 (-1.16%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Dyne Therapeutics Inc NASDAQ:DYN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.39 -1.16% 33.30 31.40 40.26 33.40 32.64 33.00 579,554 01:00:00

Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

05/01/2024 12:30pm

GlobeNewswire Inc.


Dyne Therapeutics (NASDAQ:DYN)
Historical Stock Chart


From Dec 2023 to Jun 2024

Click Here for more Dyne Therapeutics Charts.

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 2:15 p.m. PT (5:15 p.m. ET).

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 30 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com, and follow us on X, LinkedIn and Facebook.

Contact:

Amy Reillyareilly@dyne-tx.com 857-341-1203

1 Year Dyne Therapeutics Chart

1 Year Dyne Therapeutics Chart

1 Month Dyne Therapeutics Chart

1 Month Dyne Therapeutics Chart

Your Recent History

Delayed Upgrade Clock